Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

T/NK Cell-Associated Transcriptomic Profile Informs Response to FLT3 Inhibitors in Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 2916.

https://doi.org/10.1182/blood-2024-205994

Published: 2024

Journal Articles

T Cell/Natural Killer (NK) Cell Transcriptional Profiles Are Associated with Response to Gilteritinib in FLT3 -Mutated Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 2947.

https://doi.org/10.1182/blood-2023-184741

Published: 2023

Journal Articles

A Comparison of Droplet Digital PCR and RT-qPCR for BCR-ABL1 Monitoring in Chronic Myeloid Leukemia

Carmen Fava, Paola Berchialla, PhD, Jessica Petiti, PhD, Maria Teresa Bochicchio, Barbara Izzo, PhD, Emilia Giugliano, Emanuela Ottaviani, Santa Errichiello, PhD, Giovanna Rege Cambrin, MD PhD, Claudia Venturi, Luigiana Luciano, Filomena Daraio, Daniele Calistri, Alessandro Martino, Giuseppe Saglio, MD, Giovanni Martinelli, MD, Fabrizio Pane, MD, Daniela Cilloni, MD PhD, Enrico Marco Gottardi

Blood (2019) 134 (Supplement_1): 2092.

https://doi.org/10.1182/blood-2019-125614

Published: 2019

Journal Articles

An Italian Multicentre Study Using Different Digital PCR Instruments on BCR-ABL1 Positive Patients at Different Levels of CML Disease

Filomena Daraio, PhD, Emilia Giugliano, Carmen Fava, MD PhD, Roberta Lorenzatti, Dr., Marta Varotto, Dr., Davide Barberio, Dr., Simona Bernardi, PhD, Barbara Izzo, PhD, Santa Errichiello, PhD, Maria Teresa Bochicchio, Claudia Venturi, Dr., Francesco Albano, MD, Giuseppe Saglio, MD PhD, Fabrizio Pane, MD, Giovanni Martinelli, MD, Giorgina Specchia, MD, Domenico Russo, MD, Enrico Marco Gottardi, Dr.

Blood (2017) 130 (Supplement 1): 4176.

https://doi.org/10.1182/blood.V130.Suppl_1.4176.4176

Published: 2017

Journal Articles

Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR 4.0 , MR 4.5 And MR 5.0 ) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR)

Blood (2016) 128 (22): 3096.

https://doi.org/10.1182/blood.V128.22.3096.3096

Published: 2016

Journal Articles

One-Step Quantitative Molecular Approach for Detection of BCR/ABL1 Rearrangement and for Monitoring of Minimal Residual Disease in CML Patients: An Inter Laboratory Study

Filomena Daraio, PhD, Maria Teresa Bochicchio, Dr., Barbara Izzo, PhD Prof., Claudia Venturi, Dr., Santa Errichiello, PhD, Francesca Crasto, Dr., Giovanna Rege-Cambrin, MD, Roberta Lorenzatti, Dr., Carmen Fava, MD, Fausto Castagnetti, MD, Fabrizio Pane, MD Prof., Giovanni Martinelli, MD Prof., Giuseppe Saglio, MD Prof., Enrico Marco Gottardi, Dr.

Blood (2016) 128 (22): 5423.

https://doi.org/10.1182/blood.V128.22.5423.5423

Published: 2016

Journal Articles

Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia

Blood (2015) 126 (23): 2513.

https://doi.org/10.1182/blood.V126.23.2513.2513

Published: 2015

Journal Articles

Clinical Relevance of Low Burden BCR-ABL1 Mutations Detectable By Amplicon Deep Sequencing (DS) in Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients (pts): The Type of Mutation Matters

Simona Soverini, PhD, Caterina De Benedittis, PhD, Claudia Venturi, PhD, Cristina Papayannidis, MD PhD, Manuela Mancini, PhD, Katerina Machova Polakova, Domenico Russo, MD PhD, Paola Bresciani, MD, Alessandra Iurlo, MD PhD, Elisabetta Abruzzese, MD, Federica Sorà, MD PhD, Michele Baccarani, Michele Cavo, MD, Torsten Haferlach, Giovanni Martinelli, MD PhD

Blood (2015) 126 (23): 2489.

https://doi.org/10.1182/blood.V126.23.2489.2489

Published: 2015

Journal Articles

Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients

Blood (2015) 126 (23): 3198.

https://doi.org/10.1182/blood.V126.23.3198.3198

Published: 2015

Journal Articles

Long-Term Outcome to First-Line Imatinib according to 2013 European LeukemiaNet Response Criteria: a GIMEMA CML WP Analysis

Blood (2015) 126 (23): 2792.

https://doi.org/10.1182/blood.V126.23.2792.2792

Published: 2015

Journal Articles

Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome

Blood (2014) 124 (21): 484.

https://doi.org/10.1182/blood.V124.21.484.484

Published: 2014

Journal Articles

Five-Year Outcome of 215 Newly Diagnosed Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib-Based Regimens: A Gimema CML Working Party Analysis

Blood (2014) 124 (21): 3141.

https://doi.org/10.1182/blood.V124.21.3141.3141

Published: 2014

Journal Articles

Leukemia Associated TP53 Mutations in AML Patients ARE Strongly Associated with Complex Karyotype and Poor Outcome

Anna Ferrari, PhD, Cristina Papayannidis, Carmen Baldazzi, PhD, Ilaria Iacobucci, Stefania Paolini, Antonella Padella, Viviana Guadagnuolo, PhD, Margherita Perricone, Valentina Robustelli, Claudia Venturi, Maria Chiara Abbenante, Sarah Parisi, Chiara Sartor, Francesca Volpato, Nicoletta Testoni, BSc, Giorgia Simonetti, PhD, Emanuela Ottaviani, Giovanni Martinelli, MD

Blood (2014) 124 (21): 2379.

https://doi.org/10.1182/blood.V124.21.2379.2379

Published: 2014

Journal Articles

Backtracking BCR-ABL1 Mutants in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Relapsing on Tyrosine Kinase Inhibitors with Deep Sequencing: Implications for Routine Mutation Testing

Simona Soverini, PhD, Caterina De Benedittis, Cristina Papayannidis, MD, Luca Zazzeroni, Claudia Venturi, PhD, Ilaria Iacobucci, PhD, Domenico Russo, MD PhD, Paola Bresciani, Mario Luppi, Michele Baccarani, MD, Michele Cavo, MD, Giovanni Martinelli, MD

Blood (2014) 124 (21): 2259.

https://doi.org/10.1182/blood.V124.21.2259.2259

Published: 2014

Journal Articles

Evaluation of Cepheid Xpert® BCR-ABL Monitor Assay in Three Italian Reference Centers for Monitoring of BCR-ABL Transcript Levels in CML Patients

Maria Teresa Bochicchio, Barbara Izzo, Enrico Gottardi, Biagio De Angelis, Roberta Lorenzatti, Claudia Venturi, Francesca Crasto, Caterina De Benedittis, Filomena Daraio, Emanuela Ottaviani, Alessandro Volpengo, Giuseppe Saglio, MD, Fabrizio Pane, MD, Giovanni Martinelli, MD

Blood (2014) 124 (21): 1809.

https://doi.org/10.1182/blood.V124.21.1809.1809

Published: 2014

Journal Articles

Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience

Blood (2013) 122 (21): 3911.

https://doi.org/10.1182/blood.V122.21.3911.3911

Published: 2013

Journal Articles

The e13a2 BCR-ABL1 Fusion Transcript Is a Candidate Adverse Prognostic Factor In Chronic Myeloid Leukemia Patients Treated Frontline With Imatinib Mesylate

Blood (2013) 122 (21): 1486.

https://doi.org/10.1182/blood.V122.21.1486.1486

Published: 2013

Journal Articles

Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain

Blood (2013) 122 (21): 3986.

https://doi.org/10.1182/blood.V122.21.3986.3986

Published: 2013

Journal Articles

Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis

Blood (2013) 122 (21): 2622.

https://doi.org/10.1182/blood.V122.21.2622.2622

Published: 2013

Journal Articles

Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy

Simona Soverini, Caterina De Benedittis, Katerina Machova Polakova, Adela Brouckova, Fausto Castagnetti, Gabriele Gugliotta, Francesca Palandri, Cristina Papayannidis, MD, Ilaria Iacobucci, Claudia Venturi, Manuela Mancini, Elisa Leo, Hana Klamova, Stefania Paolini, Domenico Russo, Gianantonio Rosti, Michele Baccarani, MD, Michele Cavo, Giovanni Martinelli

Blood (2013) 122 (21): 380.

https://doi.org/10.1182/blood.V122.21.380.380

Published: 2013

NARROW

T/NK Cell-Associated Transcriptomic Profile Informs Response to FLT3 Inhibitors in Acute Myeloid Leukemia

T Cell/Natural Killer (NK) Cell Transcriptional Profiles Are Associated with Response to Gilteritinib in FLT3 -Mutated Acute Myeloid Leukemia

A Comparison of Droplet Digital PCR and RT-qPCR for BCR-ABL1 Monitoring in Chronic Myeloid Leukemia

An Italian Multicentre Study Using Different Digital PCR Instruments on BCR-ABL1 Positive Patients at Different Levels of CML Disease

Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR 4.0 , MR 4.5 And MR 5.0 ) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR)

One-Step Quantitative Molecular Approach for Detection of BCR/ABL1 Rearrangement and for Monitoring of Minimal Residual Disease in CML Patients: An Inter Laboratory Study

Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia

Clinical Relevance of Low Burden BCR-ABL1 Mutations Detectable By Amplicon Deep Sequencing (DS) in Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients (pts): The Type of Mutation Matters

Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients

Long-Term Outcome to First-Line Imatinib according to 2013 European LeukemiaNet Response Criteria: a GIMEMA CML WP Analysis

Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome

Five-Year Outcome of 215 Newly Diagnosed Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib-Based Regimens: A Gimema CML Working Party Analysis

Leukemia Associated TP53 Mutations in AML Patients ARE Strongly Associated with Complex Karyotype and Poor Outcome

Backtracking BCR-ABL1 Mutants in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Relapsing on Tyrosine Kinase Inhibitors with Deep Sequencing: Implications for Routine Mutation Testing

Evaluation of Cepheid Xpert® BCR-ABL Monitor Assay in Three Italian Reference Centers for Monitoring of BCR-ABL Transcript Levels in CML Patients

Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience

The e13a2 BCR-ABL1 Fusion Transcript Is a Candidate Adverse Prognostic Factor In Chronic Myeloid Leukemia Patients Treated Frontline With Imatinib Mesylate

Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain

Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis

Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only